Body mass index and prognosis in HER2-positive metastatic breast cancer patients

被引：0

作者：

Poletto, E. ^{[1
]}

Minisini, A. M. ^{[1
]}

Ferreira, A. ^{[2
]}

Matteo, L. ^{[3
]}

Poggio, F. ^{[3
]}

Sottotetti, F. ^{[4
]}

Montemurro, F. ^{[5
]}

Pozzi, E. ^{[4
]}

Rossi, V. ^{[5
]}

Risi, E. ^{[6
]}

Dellepiane, C. ^{[7
]}

Sini, V. ^{[8
]}

Ziliani, S. ^{[9
]}

Minuti, G. ^{[10
]}

Mura, S. ^{[11
]}

Grasso, D. ^{[12
]}

Bertolini, I. ^{[13
]}

Del Mastro, L. ^{[3
]}

Puglisi, F. ^{[14
]}

机构：

[1] Azienda Osped Santa Maria Della Misericordia, Dept Oncol, Udine, Italy

[2] Hosp Santa Maria, Inst Med Mol, Dept Med Oncol, Lisbon, Portugal

[3] IRCCS AOU San Martino IST, UO Oncol Med 2, Genoa, Italy

[4] Fdn Maugeri IRCCS, Unita Dipartimentale Oncol Med, Pavia, Italy

[5] Ist Candiolo IRCCS, Unit Invest Clin Oncol, Candiolo, Italy

[6] Univ Roma La Sapienza, Dept Radiol Oncol & Human Pathol, Oncol Unit B, I-00185 Rome, Italy

[7] IRCCS AOU San Martino IST, Clin Oncol Med, Genoa, Italy

[8] Univ Roma La Sapienza, St Andrea Hosp, Oncol Unit, I-00185 Rome, Italy

[9] Osped San Paolo, Oncol Med, Savona, Italy

[10] Ist Tumori Toscano, Dept Med Oncol, Livorno, Italy

[11] Osped Santissima Annunziata, Dept Med Oncol, Sassari, Italy

[12] IRCCS San Matteo Univ Hosp Fdn, Med Oncol, Pavia, Italy

[13] Azienda Osped Univ Pisana, Dept Oncol, Polo Oncol, Pisa, Italy

[14] Univ Hosp, Dept Oncol, Udine, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)30811-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1861

引用

页码：S285 / S286

页数：2

共 50 条

[1] Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer
Martel, Samuel
Poletto, Elena
Ferreira, Arlindo R.
Lambertini, Matteo
Sottotetti, Federico
Bertolini, Ilaria
Montemurro, Filippo
Bernardo, Antonio
Risi, Emanuela
Zanardi, Elisa
Ziliani, Serena
Mura, Silvia
Dellepiane, Chiara
Del Mastro, Lucia
Minisini, Alessandro Marco
Puglisi, Fabio
BREAST, 2018, 37 : 142 - 147
[2] Updates in HER2-Positive Metastatic Breast Cancer
Gadi, V. K.
Iyengar, Neil
Isaacs, Claudine
Kaklamani, Virginia
ONCOLOGY-NEW YORK, 2021, 35 (09): : 588 - 591
[3] Margetuximab in HER2-positive metastatic breast cancer
Gradishar, William J.
O'Regan, Ruth
Rimawi, Mothaffar F.
Nordstrom, Jeffrey L.
Rosales, Minori K.
Rugo, Hope S.
FUTURE ONCOLOGY, 2023, 19 (16) : 1099 - 1112
[4] Therapy for HER2-Positive Metastatic Breast Cancer
Dekker, Tim J. A.
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25):
[5] Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients
Cantini, Luca
Pistelli, Mirco
Merloni, Filippo
Fontana, Andrea
Bertolini, Ilaria
De Angelis, Claudia
Bastianelli, Lucia
Della Mora, Arianna
Santinelli, Alfredo
Savini, Agnese
Maccaroni, Elena
Diodati, Lucrezia
Falcone, Alfredo
Berardi, Rossana
CLINICAL BREAST CANCER, 2020, 20 (01) : E89 - E98
[6] How we treat patients with metastatic HER2-positive breast cancer
Nader-Marta, G.
Martins-Branco, D.
de Azambuja, E.
ESMO OPEN, 2022, 7 (01)
[7] Neratinib Plus Capecibine in Patients With HER2-Positive Metastatic Breast Cancer
Mo, Dun-Chang
Luo, Peng-Hui
Huang, Jian-Feng
Huang, Shang-Xiao
Wang, Han-Lei
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03) : 252 - +
[8] Prognosis of HER2-positive Breast Cancer in the past and today
Lorenz, Judith
GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (10) : 990 - 990
[9] Treatment of HER2-Positive Metastatic Breast Cancer REPLY
Swain, Sandra M.
Clark, Emma
Baselga, Jose
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (20): : 1964 - 1965
[10] Therapy for HER2-Positive Metastatic Breast Cancer REPLY
Winer, Eric P.
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25):

← 1 2 3 4 5 →